The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
Open accessAbstract
PURPOSE: To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. METHODS: ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended care options. RESULTS: A total of 41 articles met eligibility criteria and form the evidentiary basis for the guideline recommendations. RECOMMENDATIONS: Patients undergoing neoadjuvant therapy should be managed by a multidisciplinary care team. Appropriate candidates for neoadjuvant therapy include patients with inflammatory breast cancer and those in whom residual disease may prompt a change in therapy. Neoadjuvant therapy can also be used to reduce the extent of local therapy or reduce delays in initiating therapy. Although tumor histology, grade, stage, and estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) expression should routinely be used to guide clinical decisions, there is insufficient evidence to support the use of other markers or genomic profiles. Patients with triple-negative breast cancer (TNBC) who have clinically node-positive and/or at least T1c disease should be offered an anthracycline- and taxane-containing regimen; those with cT1a or cT1bN0 TNBC should not routinely be offered neoadjuvant therapy. Carboplatin may be offered to patients with TNBC to increase pathologic complete response. There is currently insufficient evidence to support adding immune checkpoint inhibitors to standard chemotherapy. In patients with hormone receptor (HR)-positive (HR-positive), HER2-negative tumors, neoadjuvant chemotherapy can be used when a treatment decision can be made without surgical information. Among postmenopausal patients with HR-positive, HER2-negative disease, hormone therapy can be used to downstage disease. Patients with node-positive or high-risk node-negative, HER2-positive disease should be offered neoadjuvant therapy in combination with anti-HER2-positive therapy. Patients with T1aN0 and T1bN0, HER2-positive disease should not be routinely offered neoadjuvant therapy. Additional information is available at www.asco.org/breast-cancer-guidelines .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Self-citationPembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Self-citationGianni, L., Pienkowski, T., Im, Y.-H., Roman, L., Tseng, L.-M., Liu, M.-C., Lluch, A., Staroslawska, E., de la Haba-Rodriguez, J., Im, S.-A., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70336-9 · Cited by 2,374
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.
Fisher, B., Bryant, J., Wolmark, N., Mamounas, E., Brown, A., Fisher, E. R., Wickerham, D. L., Begovic, M., DeCillis, A., Robidoux, A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2672 · Cited by 2,165
Ferrell, B. R., Temel, J. S., Temin, S., Alesi, E. R., Balboni, T. A., Basch, E. M., Firn, J. I., Paice, J. A., Peppercorn, J. M., Phillips, T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1474 · Cited by 2,117
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Fisher, B., Brown, A., Mamounas, E., Wieand, S., Robidoux, A., Margolese, R. G., Cruz, A. B., Fisher, E. R., Wickerham, D. L., Wolmark, N., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.7.2483 · Cited by 1,801
Rastogi, P., Anderson, S. J., Bear, H. D., Geyer, C. E., Kahlenberg, M. S., Robidoux, A., Margolese, R. G., Hoehn, J. L., Vogel, V. G., Dakhil, S. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0235 · Cited by 1,789 · cited 2×
“in peer-reviewed journals; (2) editorials, commentaries, letters, news articles, case reports, and narrative reviews; (3) published in a non-English language; (4) RCTs with , 100 patients total across treatment arms; (5) trials that evaluated only clinical response, biomarker end points, or breast-conserving surgery (…”
BackgroundResultMohile, S. G., Dale, W., Somerfield, M. R., Schonberg, M. A., Boyd, C. M., Burhenn, P. S., Canin, B., Cohen, H. J., Holmes, H. M., Hopkins, J. O., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.8687 · Cited by 1,479
Self-citation
Cited by
Breast Cancer Statistics, 2022
Giaquinto, A. N., Sung, H., Miller, K. D., Kramer, J. L., Newman, L. A., Minihan, A., Jemal, A., & Siegel, R. L. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21754 · Cited by 2,286
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, M. J., Carey, L. A., Dawood, S., Del Mastro, L., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2023.11.016 · Cited by 1,008
Self-citationDeep learning in histopathology: the path to the clinic
van der Laak, J., Litjens, G., & Ciompi, F. (2021) · Nature Medicine · doi:10.1038/s41591-021-01343-4 · Cited by 902
Advances in systemic therapies for triple negative breast cancer
Leon-Ferre, R. A., & Goetz, M. P. (2023) · BMJ · doi:10.1136/bmj-2022-071674 · Cited by 507
The emerging role of photoacoustic imaging in clinical oncology
Lin, L., & Wang, L. V. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00615-3 · Cited by 469
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality
Kerr, A. J., Dodwell, D., McGale, P., Holt, F., Duane, F., Mannu, G., Darby, S. C., & Taylor, C. W. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102375 · Cited by 307
Recent updates on innovative approaches to overcome drug resistance for better outcomes in cancer
Sharma, M., Bakshi, A. K., Mittapelly, N., Gautam, S., Marwaha, D., Rai, N., Singh, N., Tiwari, P., Agarwal, N., Kumar, A., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.04.007 · Cited by 84
Li, B., Li, F., Liu, Z., Xu, F., Ye, G., Li, W., Zhang, Y., Zhu, T., Shao, L., Chen, C., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.10.004 · Cited by 48
Skarping, I., Larsson, M., & Förnvik, D. (2022) · European Radiology · doi:10.1007/s00330-021-08306-w · Cited by 44
Oba, T., Kajihara, R., Yokoi, T., Repasky, E. A., & Ito, F. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0939 · Cited by 26
Breast cancer: miRNAs monitoring chemoresistance and systemic therapy
Singh, S., Saini, H., Sharma, A., Gupta, S., Huddar, V. G., & Tripathi, R. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1155254 · Cited by 25
Advances in 3D Culture Models to Study Exosomes in Triple-Negative Breast Cancer
Yousafzai, N. A., El Khalki, L., Wang, W., Szpendyk, J., & Sossey-Alaoui, K. (2024) · Cancers · doi:10.3390/cancers16050883 · Cited by 20
Metadata
- Authors
- Korde, L. A., Somerfield, M. R., Carey, L. A., Crews, J. R., Denduluri, N., Hwang, E. S., Khan, S. A., Loibl, S., Morris, E. A., Perez, A., Regan, M. M., Spears, P. A., Sudheendra, P. K., Symmans, W. F., Yung, R. L., Harvey, B. E., & Hershman, D. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-05-01
- Volume
- 39
- Issue
- 13
- Pages
- 1485-1505
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3122861570
- Cited by
- 1,040
- References
- 119
- FWCI
- 50.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.